Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Summary

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Timeline

Start

2025-08-07

Primary completion

2030-05

Completion

2030-05

Drugs

Indications